Navigation Links
Freezing Kidney Cancers Shows Promise

Study found noninvasive technique eradicated smaller tumors

FRIDAY, March 13 (HealthDay News) -- Most kidney cancer tumors can be eradicated using a noninvasive freezing technique that eliminates the need for surgery, a pair of studies from Johns Hopkins Hospital suggests.

The findings have prompted the researchers to claim that the procedure, known as cryoablation, should be the new "gold standard" of treatment for kidney cancer -- although not all cancer experts agree.

"Here we found that we can very successfully treat kidney cancer tumors, and get rid of them completely, by essentially freezing them," said the lead author of one of the two studies, Dr. Christos Georgiades, an interventional radiologist at Hopkins.

"The only caveat," he cautioned, "is that the data we have concerns treating kidney cancers that are smaller than 5 centimeters -- about 2 inches -- in diameter. But I would say that for tumors that are up to 4 centimeters in diameter, cryoablation -- freezing -- should be the first option for treatment, not surgery."

Georgiades and his colleagues presented the findings Monday at the Society of Interventional Radiology annual meeting in San Diego.

Cryoablation uses high-tech imaging to locate tumors, along with small probes inserted through a tiny hole in the skin to direct freezing cold to the trouble spot. It is usually performed as a one-day outpatient treatment and is already widely available in hospitals throughout the United States.

However, the Hopkins team pointed out that current protocols place solid emphasis on surgical removal (laparoscopy) as the standard approach to kidney cancer, with cryoablation relegated to a fallback role for high-risk patients who are battling multiple illnesses, limited kidney function or multiple or recurring tumors or who have problems undergoing anesthesia.

The study authors noted that kidney cancer strikes 54,000 Americans -- mostly older adults -- every year and ultimately takes the lives of 13,000 people a year.

Although the risk for developing the cancer is about one in 75, Georgiades and his team point out that 75 percent of kidney cancer diagnoses are made while the tumor is still relatively small and potentially most responsive to cryoablation.

For their study, the researchers tracked the success of cryoablation in tackling 73 renal-mass tumors, 10 of them benign, in 68 people who averaged 67 years old. CT or MRI imaging was done three, six and 12 months after the procedure to assess tumor status. Participants were followed for two to three years.

They found that cryoablation destroyed localized tumors up to 4 centimeters in diameter 100 percent of the time. Tumors up to 7 centimeters in size (about 3 inches) were destroyed "nearly" 100 percent of the time, and in the few cases in which tumor size was large -- about 10 centimeters, or roughly 4 inches, in diameter -- cryoablation was successful two-thirds of the time, the study found.

There was no evidence of any cancerous spread to areas outside the kidney during follow-up, the authors noted.

In the second Hopkins study, researchers spent up to two years tracking complications after cryoablation among 73 people who had 81 procedures. No treatment-related deaths occurred, and though there were complications in just over 7 percent of the cases, the team concluded that the technique has an "excellent safety profile."

Despite the findings, Georgiades said, problems with tumor location mean that there will always be people who need surgery.

"The great success we had with cryoablation assumes that not only is the tumor small enough but also that we can successfully get to it from the outside with probes," he explained. "So tumors that are too deep or too close to vital organs might not be targetable," he said, noting that no such patients were included in the study. "This type of patient will need surgery. But this problem would affect only maybe one-quarter to one-third of patients. For the rest, cryoablation should be the first option."

Georgiades said that freezing is already the "first-line treatment" for small kidney cancer tumors at Hopkins.

However, Dr. Paul Russo, an attending urologic oncological surgeon at Memorial Sloan-Kettering Cancer Center in New York City, argued strongly against the notion that cryoablation now be considered the "gold standard" for kidney cancer treatment.

"To suggest that freezing should be the new 'gold standard' is … very naive because the treatment of small renal masses is a highly complex area in kidney tumor management, and ablation is largely an investigative technique that simply has not yet been studied well."

"For example, one of the ways in which this particular study is flawed is that, after ablation, they conducted much too short a follow-up to perform any kind of meaningful survival analysis," Russo noted. "Almost nothing happens in the first year. To assess the effectiveness of any kidney cancer treatment you really need active surveillance for at least a five-year period, which they didn't do."

"The study's conclusions are a huge overstatement," he added. "Freezing is just one treatment option. Nothing more."

More information

The American Cancer Society has more on kidney cancer.

SOURCES: Christos Georgiades, M.D., Ph.D., interventional radiologist, Johns Hopkins Hospital, Baltimore; Paul Russo, M.D., attending urologic oncological surgeon, Memorial Sloan-Kettering Cancer Center, New York City, and professor, urology, Cornell University, Ithaca, N.Y.; March 9, 2009, presentations, Society of Interventional Radiology annual meeting, San Diego

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Freezing Ovaries Preserves Fertility, Scientists Report
2. Tissue-Freezing Technique Effective Against Prostate Cancer
3. Pacific Fertility Center Announces Breakthrough in Egg Freezing Technology
4. Satellite Healthcare Celebrates World Kidney Day and National Kidney Month
5. DaVita Raises Awareness on World Kidney Day
6. The navel: A single, safe surgical access route for kidney extraction
7. Living Kidney Donation Chains May Help More Get Transplants
8. Kidney Care Partners and National Minority Quality Forum Call for Prevention Programs in Disease Hot Spots
9. Upcoming World Kidney Day Underscores Role of Low-Cost Lab Tests in Combating High-Cost Kidney Disease
10. VIDEO from Medialink and the Society of Interventional Radiology: Prostate and Kidney Cancer - New Life-Changing Developments
11. Miami Heat Fan Favorite and NBA All-Star Alonzo Mourning Visits Florida Legislature, Governor to Urge Needed Coverage for Florida Kidney Patients
Post Your Comments:
Related Image:
Freezing Kidney Cancers Shows Promise
(Date:6/27/2016)... ... June 27, 2016 , ... recently awarded their ... Eyeglasses . , Millions of individuals in the United States and Canada wear eyeglasses. ... way to both correct vision and make a fashion statement. Even celebrities use glasses ...
(Date:6/26/2016)... ... ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect Plugin ... whole new perspective by using the title layers in ProSlice Levels to split-up ... Levels contains over 30 Different presets to choose from. FCPX users can ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
Breaking Medicine Technology: